Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026
Rhea-AI Summary
Vivani Medical (NASDAQ: VANI) announced that CEO Adam Mendelsohn will present a company overview at the Jefferies Global Healthcare Conference in New York on June 4, 2026, from 11:05 a.m. to 11:35 a.m. ET. A replay will be available for 90 days on Vivani’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – VANI
In the May 28 session, VANI gained 0.78%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Q1 2026 earnings | Positive | +3.5% | Reported Q1 results, cash and commitments funding operations into first half 2027. |
| Mar 26 | FY 2025 results | Positive | -1.9% | Fourth quarter and 2025 update with GLP‑1 implant progress and extended runway. |
| Jan 29 | Clinical trial update | Positive | +1.3% | Cortigent Orion six-year feasibility results showing functional devices and low electrode loss. |
| Jan 27 | Equity offering closing | Negative | +8.0% | Closed registered direct and private placement raising about $4.5M at $1.48 per share. |
| Jan 25 | Equity offering pricing | Negative | -6.8% | Priced best-efforts registered direct and concurrent private placement at $1.48 per share. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often saw modestly positive reactions to clinical and business updates, while offerings produced mixed but sometimes strong price moves.
Over the last six months, Vivani issued earnings updates, clinical news and equity offerings. Q1 2026 results on May 13 highlighted cash runway into 2027 and saw a modest positive reaction. Earlier, 2025 results and GLP‑1 implant progress on March 26 drew a small decline despite clinical momentum. An Orion system study update on January 29 was received positively. Two January offerings produced opposite reactions, underscoring sensitivity to financing terms. Today’s Jefferies conference appearance fits within this cadence of ongoing visibility-building.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the Jefferies Global Healthcare Conference taking place June 2-4, 2026 in New York, New York.
Details of Dr. Mendelsohn’s presentation are as follows:
Date: Thursday, June 4, 2026
Time: 11:05 a.m. - 11:35 a.m. Eastern Time
Location: New York Marriott Marquis, 1535 Broadway
Following the presentation, a replay will be available for 90 days on the Investors section of the Vivani corporate website at https://vivani.com.
More information about the Jefferies Global Healthcare Conference can be found at https://www.jefferies.com/events/global-healthcare-conference-in-new-york/.
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development thereof, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. There may be additional risks that the Company consider immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 26, 2026. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.
Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462
